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Adoptive T-cell therapy has recently shown promise in initiating a lasting anti-tumor
response with spectacular therapeutic success in some cases. SpecificT-cell therapy, how-
ever, is limited since a number of cancer cells are not recognized by T cells due to various
mechanisms including the limited availability of tumor-specific T cells and deficiencies in
antigen processing or major histocompatibility complex (MHC) expression of cancer cells.
To make adoptive cell therapy applicable for the broad variety of cancer entities, patient’sT
cells are engineered ex vivo with pre-defined specificity by a recombinant chimeric antigen
receptor (CAR) which consists in the extracellular part of an antibody-derived domain for
binding with a “tumor-associated antigen” and in the intracellular part of a T-cell receptor
(TCR)-derived signaling moiety for T-cell activation. The specificity of CAR-mediated T-cell
recognition is defined by the antibody domain, is independent of MHC presentation and
can be extended to any target for which an antibody is available.We discuss the advantages
and limitations of MHC-independent T-cell targeting by an engineered CAR in comparison
to TCR modified T cells and the impact of the CAR activation threshold on redirected T-cell
activation. Finally we review most significant progress recently made in early stage clinical
trials to treat cancer.
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TUMOR-SPECIFIC T CELLS FOR ADOPTIVE CELL THERAPY
Experimental and clinical evidences indicate that the immune
system is capable of identifying and destroying cancer cells in a
specific fashion; tumor-infiltrating lymphocytes (TILs), expanded
ex vivo and re-administered to the patient, exhibit a powerful anti-
tumor response and induce an acute inflammatory reaction which
attracts a second, antigen-independent wave of immune cell inva-
sion into the same lesion. Adoptive TIL therapy has shown some
success in the treatment of chemotherapy resistant melanoma,
even in advanced stages of the disease (1). The procedure, how-
ever, is technically challenging since it involves the isolation of T
cells from melanoma biopsies and their amplification ex vivo to
therapeutic numbers; not every melanoma biopsy provides TILs
and allows sufficient expansion. Moreover, the range of TIL bear-
ing malignant lesions, apart from melanoma, is small limiting the
application of the strategy to a broad variety of cancer entities.
The implementation of redirected T cells in cancer therapy is
based on engineering T cells with pre-defined specificity to target
virtually every cancer cell and on the production of engineered
T cells in therapeutic numbers. To provide specificity peripheral
blood T lymphocytes were ex vivo engineered with a recombinant
T-cell receptor (TCR) of known specificity which recognizes cog-
nate peptide-loaded major histocompatibility complexes (pMHC)
of a so-called tumor-associated antigen (TAA). Such TCR engi-
neered T cells showed promise in clinical trials (1, 2). Some
conceptual deficits, however, limit the broad application of TCR
engineered T cells including the HLA restriction, the dependency
on adequate major histocompatibility complex (MHC) expression
by tumor cells, the limited number of peptide-MHC complexes
identified so far which can be used for screening and the potential
mispairing with the endogenous TCR producing novel, unfore-
seen specificities which might induce severe auto-immunity after
adoptive transfer (3).
Whereas the T-cell therapy using ex vivo expanded patients’
TILs leads to significant clinical effect in patients with metasta-
tic melanoma (1), difficulties are arising when engineering T cells
with a recombinant TCR, in particular when non-immunogenic
tumor-associated self-antigens are targeted (4). In a pre-clinical
tumor model the treatment with TCR engineered T cells alone
was without effect while the combination of vaccination with TCR
modified T-cell transfer was synergistic.
In this situation, Zelig Eshhar, Weizmann Institute, proposed
to redirect T cells by a recombinant receptor molecule, a chimeric
antigen receptor (CAR), which in the extracellular part consists of
an antibody with pre-defined binding specificity to a broad vari-
ety of targets and in the intracellular part of a T-cell activation
domain (5). Such CAR modified T cells became generally known
as “T-bodies” (5). In contrast to the TCR, the archetypical CAR
is composed of one polypeptide chain (Figure 1). The binding
domain is mostly a recombinant antibody in the single chain for-
mat consisting of the variable domain of the heavy and light chain
linked by a short synthetic peptide (scFv). The extracellular part
of a receptor molecule, for instance the NK cell-derived NKG2D
ligands (6) and the surface NKp-30 (7) receptor, were also success-
fully integrated into the conventional CAR structure instead of the
classical antibody-derived binding domain. The CAR intracellular
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FIGURE 1 | Modular composition of the chimeric antigen receptor (CAR)
compared to theT-cell receptor (TCR). The TCR binds to cognate
peptide-loaded MHC (pMHC) by the TCR α and β chains, forms the
immunological synapse by clustering accessory components including CD3ζ
and CD28, and initiates the downstream signaling pathway for T-cell activation
through phosphorylation of the CD3ζ ITAM motives. The CAR, in contrast, is
composed of one polypeptide chain; the extracellular single chain fragment of
variable region (scFv) antibody domain binds to the target antigen in a
MHC-independent fashion. Upon CAR clustering, the intracellular CD3ζ chain,
with or without costimulation through members of the CD28 family, initiates
the downstream signaling for T-cell activation. Co-receptors may modulate
CAR activity. In contrast to a first generation (1°) CAR, second (2°), and third
(3°) generation CARs harbor in addition one or more costimulatory moieties in
their intracellular part.
signaling domain is preferentially derived from the CD3 ζ-chain
of the TCR/CD3 complex or, alternatively, from the γ-chain of
the high affinity IgE Fc receptor-I (FcεRI). Binding with cognate
antigen on the tumor cell surface results in CAR clustering on the
engineered T-cell with the consequence that the immunoreceptor
tyrosine-based activation motifs (ITAMs) of the signaling moi-
ety become phosphorylated and initiate a downstream signaling
cascade which finally induces T-cell amplification, cytokine secre-
tion, and cytolytic activity of the CAR T-cell toward the cognate
tumor cell.
CAR T cells overcome some limitations of the TCR-based
strategy by targeting cells in an MHC- and dendritic cell (DC)-
independent fashion. The properties of a CAR and TCR differ
substantially in respect to target binding and subsequent T-cell
activation. For instance these are in particular the TCR avidity for
a given pMHC, the number of MHC molecules, the availability
of co-receptors and the moderate TCR affinity for the cognate
MHC peptide complex compared to the high affinity of the anti-
body in a CAR. On the one hand the use of antibody-based CAR
T cells enables the targeting of antigens of different composi-
tion and structure such as peptides, carbohydrates, or inorganic
compounds, and on the other hand, the TCR recognizes peptide
antigens exclusively in the context of the particular MHC and
thereby faces a limited variability. TCRs are moreover inherently
cross-reactive toward endogenous antigens (8). The potential CAR
targets thereby far outnumber their MHC presented counterparts
which can be recognized by TCR modified T cells. In this report
we review some advantages and limitations of MHC-independent
target recognition by CAR T cells and review most significant
progress recently made in early stage clinical trials to treat cancer.
THE CAR STRATEGY: ANTIBODY-MEDIATED,
MHC-INDEPENDENT ANTIGEN RECOGNITION BY
ENGINEERED T CELLS
The design of the antibody-derived CAR differs in several major
features from the TCR which physiologically mediates target
recognition by T cells (Figure 1). By using an antibody for binding,
T cells gain antibody-defined specificity: (i) T cells without CAR
or equipped with a CAR of different specificity are not activated
by the target cells; (ii) the cognate antigen needs to be on the cell
surface to trigger CAR T-cell activation, intracellular antigens are
not recognized by the CAR; and (iii) CAR-mediated T-cell acti-
vation can be specifically blocked by an antibody directed toward
the CAR binding domain (9).
As a consequence of using an antibody for binding, CARs can
redirect T cells toward targets of any chemical composition or
conformation as far as an antibody is available. Indeed, CARs
were engineered which target T cells toward carbohydrate anti-
gens like CA19-9 (10–12). The TCR, in contrast, is restricted to
the recognition of specific peptides presented by the particular
MHC. Antibody-mediated target recognition by CARs, however,
does not exclude targeting MHC presented antigens. Using an
antibody which recognizes NY-Eso-1 peptide (157–165) in the
context of HLA-A*0201,Stewart-Jones et al. engineered a CAR rec-
ognizing the MHC presented peptide analog SLLMWITQV (13).
The antibody domain used for CAR targeting was optimized by
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modification of the individual amino acids which interact between
the antibody and the peptide providing an antibody with 20-fold
improved affinity, exceeding the affinity of the respective TCR by
about 1000-fold. The high affinity antibody when engineered as
recombinant CAR on T cells conferred specific killing of HLA-
A*0201/NY-ESO-1157–165 target cells as do T cells modified with
the corresponding TCR.
BOTH CD8+ AND CD4+ T CELLS CAN BE REDIRECTED IN A
MHC-INDEPENDENT FASHION
By bypassing MHC class I and class II restriction by an antibody-
derived binding domain, CAR engineered T cells of both CD8+
and CD4+ subsets can be recruited for redirected target cell recog-
nition (9, 14, 15). Equipped with a CAR, CD4+ T cells showed
as cytolytic as do CD8+ T cells toward CAR-defined target cells.
While human CD8+ T cells predominantly use two pathways in
executing cytolysis, i.e., perforin and granzyme exocytosis and to
some extend death receptor signaling via Fas/Fas-ligand (Fas-L)
or TNF/TNF-receptor (TNF-R) (16), the mechanism of CAR-
mediated lysis by redirected CD4+ T cells was a matter of debate
for some time. Investigations utilizing mutant and knock-out mice
suggest that MHC class II restricted cytolysis by murine CD4+
T cells is predominantly mediated by the death receptor system
(17, 18) which is in contrast to MHC class I restricted cytoly-
sis by CD8+ CTLs relying mainly on perforin and granzymes.
Accordingly, murine CD8+ T cells engineered with a CAR lyse Fas
resistant target cells whereas CD4+ T lymphocytes do not (19). In
contrast to murine cells, CAR redirected human T cells mediate
cytolysis predominantly by granzyme/perforin which can be exe-
cuted independently of Fas or TNF-α signaling (14). The extent in
redirected cytolysis correlates with the amount of cytolytic effector
molecules; CAR CD4+ T cells which harbor about half amounts
of perforin and granzyme B required about twice the number
of effector cells to achieve the same cytolytic efficacy compared
to CAR redirected CD8+ T cells. CAR CD4+ T cells rapidly lyse
their targets in a short term in vitro cytotoxicity assay as do engi-
neered CD8+ T cells which is in accordance to a perforin mediated
process whereas death receptor signaling induces cytolysis of the
delayed type. CAR engineered CD4+ T cells lyse both Fas- and
TNF-resistant target cells. The observation is in accordance to a
report that non-modified human CD4+ T cells execute cytoly-
sis predominantly by granule exocytosis and not by the Fas/Fas-L
system (20). In contrast to CAR modified cells, CD4+ cells engi-
neered with a MHC class I restricted TCR were reported to lyse
exclusively those target cells that are susceptible for death recep-
tor signaling (21). Both studies, however, differ in several issues
including the use of a MHC class I-dependent TCR vs. a MHC-
independent CAR for redirecting T cells. As a consequence for
adoptive cell therapy, CAR engineered patient’s CD4+ T cells can
efficiently provide help upon CAR-mediated activation and can
eliminate tumor cells in a direct fashion and independently from
MHC class II restriction.
“AFFINITY CEILING” OF ANTIBODY-MEDIATED CAR T-CELL
ACTIVATION
CAR-mediated T-cell activation is thought to depend on and to
increase with the binding affinity to cognate antigen; however,
the interaction is likely of higher affinity than binding of the
physiological TCR to peptide loaded MHC. Two studies addressed
in detail the situation (22, 23). The Chmielewski study (22) made
use of a panel of CARs of the same backbone and same epitope
specificity but with different binding affinities. The affinities were
in the broad range of 10−7–10−11 M and were obtained upon
mutation of the parental antibody while preserving the binding
specificity. CAR T-cell activation correlated with the affinity of the
antibody binding domain when the target antigen is present in
an immobilized fashion coated onto surfaces. In contrast, when
the cognate antigen is present on the surface of the target cell, the
CAR-mediated cytotoxic effect on target cells and the release of
IFN-γ and IL-2 did not increase with the binding affinity above
threshold, which was in that example about K D= 10−8 M. While
the conditions that define the activation threshold, however, are
so far not understood on the molecular level, the study makes
clear that furthermore increase in affinity above threshold does
not improve the redirected T-cell attack toward target cells but
may result in antigen-independent T-cell activation.
The Hudecek study (23) evaluated scFv’s of different affinities
and CARs with different backbones with respect to their efficacy in
redirecting T cells. The CAR with higher binding affinity conferred
maximum T-cell activation with respect to cytokine release and
proliferation compared to the CAR with lower affinity. The redi-
rected cytolytic activity, however, was nearly the same. Although
the study confirms previous observations that increase in affin-
ity does not necessarily improve all T-cell effector functions, the
comparison of the CARs is alleviated in that two binding domains
targeting different epitopes, although in the same domain of the
targeted ROR1 molecule, were used.
A recent study explored the situation for TCR modified T cells
to determine the affinity threshold with respect to the optimal
balance between anti-tumor efficacy and auto-immunity (24).
Similar as for CAR modified T cells, TCR redirected anti-tumor
activity shows a plateau at a defined TCR affinity, likely due to
diminished contribution of TCR affinity to avidity above the
threshold. Additional differences probably lie in the ability of dif-
ferent affinity interactions eliciting different effector functions at
different antigen concentrations. The observations are in accor-
dance to the CAR situation and strongly suggest that a relatively
low affinity threshold is mandatory to avoid self-damage, that high
affinity TCRs do not necessarily improve efficacy given the close
relationship between anti-tumor activity and auto-immunity.
THE POSITION OF THE TARGETED EPITOPE MATTERS:
MEMBRANE PROXIMAL VS. DISTAL EPITOPES AS TARGETS
FOR CAR ENGINEERED T CELLS
By using an antibody for targeting, CAR engineered T cells can be
redirected toward a variety of epitopes of the same antigen as far
as the epitope is accessible to the respective antibody. The vari-
ous epitopes of a given membrane-bound molecule, however, are
not equally good targets for efficient T-cell activation. This was
shown when membrane distal and proximal epitopes of the same
membrane-bound molecule were targeted by CARs. For instance,
when targeting carcinoembryonic antigen (CEA) expressed on
gastrointestinal carcinoma cells, a higher degree of T-cell acti-
vation was obtained when epitopes closer to the cell membrane
www.frontiersin.org November 2013 | Volume 4 | Article 371 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chmielewski et al. Chimeric antigen receptor-redirected T cells
were targeted (25). The epitope itself is not the cause of the phe-
nomenon since the isolated, solid phase bound CEA induces T-cell
activation independently of the epitope position but dependent of
the antibody binding affinity. The distal epitope when expressed in
a more membrane proximal position activated CAR T cells with
higher efficiency than in the distal position indicating that the
position effect of the targeted epitope has, at least in this example,
prominent impact on T-cell activation. The accessibility of the
epitope for binding additionally impacts the efficiency in CAR-
mediated T-cell activation; in the case of CEA targeting, however,
the epitope accessibility seems not to be limiting because the dis-
tal epitope, which is thought to be more accessible than the more
proximal epitope, is superior in binding but less capable in medi-
ating CAR activation. This is in accordance with another report
which analyzed the impact of the position of the target epitope on
the structural requirements of the CAR (26). Basically the same
observation was made when targeting B-cell lymphoma associ-
ated CD22 by CAR T cells (27, 28). To explain the observation, a
kinetic-segregation model, initially proposed by Davis and van der
Merwe (29) and hypothesized also to occur in CAR engineered T
cells, is currently favored. The model suggests that targeting mem-
brane distal epitopes increases the size of the CAR-ligand clusters,
which in turn permits large phosphatase molecules such as CD45
to enter the synapse and to repress TCR signaling which is less the
case when targeting the membrane proximal epitope. The model,
however, does not exclude that accessibility and flexibility of the
targeted epitope itself may also contribute to some extent.
The best suitable target epitope and binding affinity for optimal
CAR T-cell activation remains so far to be empirically evaluated
in each case. This is of major relevance given the broad variety of
potential targets for a CAR in contrast to the TCR, the specificity
of which is restricted to MHC presented peptides.
CD28 COSTIMULATION PROVIDED BY SECOND GENERATION
CARs: MAJOR DIFFERENCES TO STIMULATION THROUGH
APCs
First generation CARs provide exclusively only one signaling
domain such as CD3ζ-, ε-, or FcεRI γ-chain to initiate redirected
activation of pre-stimulated T cells upon CAR binding with anti-
gen. To prevent engineered T cells undergoing activation-induced
cell death and anergy, CD28 costimulation simultaneously to
CD3ζ signaling is required. CD28 is the prototype of a family
of costimulatory molecules that is physiologically engaged on T
cells by binding to the respective ligands on antigen-presenting
cells (APCs). The agonistic CD28 ligands B7.1 (CD80) and B7.2
(CD86), physiologically expressed on APCs, are missing on most
cancer cells with the consequence that the CD3ζ CAR upon bind-
ing to cancer cells does not provide the costimulation required
for full activation. The limitation was overcome by linking the
intracellular signaling domain of CD28 to CD3ζ in one polypep-
tide chain of the same CAR (30–33). In this so-called “second
generation” CAR the artificial fusion of the CD28 and CD3ζ sig-
naling domains facilitates Lck-mediated CD28 phosphorylation
that binds and activates phosphatidylinositol 3-kinase for down-
stream signaling, resulting in full T-cell activation and IL-2 release.
Other costimulatory molecules of the TNF-receptor family includ-
ing 4-1BB (CD137) and OX40 (CD134) can also be integrated
into the same CD3ζ CAR molecule or combined with CD28 in
a “third generation” CAR. This type of CAR has the advantage
that T-cell costimulation occurs in an APC-independent fashion
and is accompanied by suppressing inhibitory and/or strengthen-
ing stimulatory signals, each costimulatory signal modulating the
T-cell effector function in a specific fashion (34). CD28 costimu-
lation is integrated into most currently used CARs because CD28
sustains survival and prolongs polyclonal expansion of engineered
T cells without the need of B7–CD28 engagement (35). CD28
co-signaling induces IL-2 that is used in an autocrine fashion by
redirected T cells to increase their amplification (36). CD28-CD3ζ
CAR signaling moreover counteracts transforming growth factor-
β1 (TGF-β1)-mediated repression in T-cell amplification (37).
Both prevention from AICD and increased amplification produce
prolonged T-cell persistence and an improved anti-tumor attack.
Other beneficial properties and some draw backs were recently
discussed in more detail (38). Taking advantage of CD28 of other
costimulatory moieties like 4-1BB, second generation CARs are
currently being explored in early phase clinical trials.
The impact of CAR provided CD28 costimulation on the
threshold of antigen-dependent, APC-independent T-cell activa-
tion was addressed by using a panel of CARs targeting T cells in
the absence of agonistic CD28 ligands (39). CAR provided CD28
costimulation increases cytokine secretion but does not impact the
activation threshold or“affinity ceiling,”above which an increase in
affinity does not increase T-cell activation. CD28 did not increase
sensitivity toward target cells with intermediate or low densities
of the respective target antigen. Additional CD28–B7 engagement
did not further alter CD28-CD3ζ CAR-mediated T-cell activa-
tion. In the presence of a CD3ζ CAR, however, B7 engagement
increased IFN-γ secretion indicating that the physiological CD28
costimulation through APCs cooperates with CAR-driven T-cell
activation.
Another aspect concerns the fact that most target antigens for
adoptive immunotherapy are not exclusively expressed on tumor
cells but broadly present on a variety of healthy tissues, although
frequently at lower levels. Since CAR provided CD28 costimula-
tion in the absence of APCs does not alter the activation threshold,
costimulation does not impact the selectivity of a redirected T-
cell attack in peripheral tissues, does not lower the affinity ceiling
and antigen-dependent threshold of CAR redirected T cells and
thereby protects healthy cells with physiological levels of antigen
from a T-cell attack.
With respect to costimulation, there are some fundamental dif-
ferences in the physiologic vs. CAR-mediated T-cell activation. To
induce full T-cell activation, the peptide loaded MHC has to inter-
act with the TCR in a form that allows the appropriate synapse
formation on the T-cell and to recruit costimulatory molecules
which increase stability during early stages in this process. CD28
recruitment by B7 engagement on APCs sustains formation of the
immunological synapse which is accompanied by lower amounts
of antigen required for T-cell activation. During T-cell–APC inter-
actions, in particular during early activation events, CD28–B7
binding potentiates synapse formation by increasing the density
of the synapse components through approximation of the inter-
acting membranes (40); increased clustering integrates the TCR
with costimulatory signaling which can compensate for weak TCR
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signals (41). The TCR binding threshold exhibits a sharp cutoff
between full T-cell activity and no activity; the activation efficiency
correlates with the TCR binding to the cognate peptide–MHC on
APCs (42). Optimal CD28 costimulation occurs upon high-avidity
engagement of dimeric B7.1, followed by dimer dissociation,CD28
down-regulation, and B7.1 internalization (43). CD28-B7 interac-
tions with APCs sustain synapse formation which facilitates T-cell
signaling upon low affinity target engagement depending on the
extend of supra-molecular clustering (44). This mechanism is in
contrast to CD28 CAR-mediated T-cell activation, in particular,
the avidity of CAR binding is generally higher than of physiologi-
cal TCR–MHC interactions. Whether the CAR synapse is formed
in the same way as the TCR recruits additional components is so
far not resolved. There are, however, some cooperative interac-
tions between the CAR and downstream signaling molecules since
additional B7.1-CD28 costimulation improves cytokine secretion
initiated by CAR signaling.
CAR BASED ADOPTIVE CELL THERAPY GAINED
SUBSTANTIAL SUCCESS IN RECENT EARLY PHASE TRIALS
Adoptive cell therapy with CAR engineered T cells is currently
being evaluated in a number of early phase trials, some of them
are listed in Table 1. Patient’s T cells are modified ex vivo by retro-
or lenti-viral gene transfer with the respective CAR, amplified to
therapeutically relevant numbers and given back to the patient by
transfusion. Some of these trials produced encouraging evidence
of clinical efficacy. CD19-specific CAR T cells induced complete
and lasting remission of refractory CD19+ B-cell chronic lympho-
cytic leukemia (CLL) in all of the first three reported patients (44,
45). When successfully engrafted, CAR T cells expanded in vivo
more than 1000-fold compared to the initial level, persisted in the
peripheral blood and bone marrow for at least 6 months, and con-
tinued to express the CAR. T cells were effective in an anti-tumor
response even at low dosage levels of about 1.5× 105 cells/kg (45).
The prolonged persistence of CD28-4-1BB-CD3ζ CAR modified
T cells is probably due to two effects, the cooperation of cos-
timulation in sustaining T-cell survival in the long-term and the
repetitive re-stimulation by CD19+ healthy B cells and their prog-
enitors which are also targets for the anti-CD19 CAR T cells. Apart
from grade-3 tumor lysis syndrome and a cytokine storm, T-cell
infusions had no other acute toxic effects in that trial. Interestingly,
there was a delayed increase in the pro-inflammatory cytokines
IFN-γ and IL-6, which paralleled the clinical symptoms and coin-
cided with the elimination of leukemia cells from the bone marrow.
The clinical application of an IL-6 neutralizing antibody, notewor-
thy, reduced clinical manifestation of the cytokine storm. The same
CAR is currently being evaluated in the treatment of pediatric
CD19+ acute leukemia with spectacular success, however, relapse
of CD19− leukemia during therapy was also observed in one case
(46). In previous trials, CAR T cells expanded less and objective
tumor responses were modest although clearly documented in two
out of three patients (47–50).
Despite recent success, two fatal serious adverse events occurred
after infusion of CAR T cells, one of which is at least in part con-
tributed to the CAR targeting specificity. “On-target off-organ”
activation of the CAR T cells occurred in the NIH trial based on the
fact that the targeted Her2/neu (ErbB2) is ubiquitously expressed
on healthy tissues (50). The other adverse event after treatment of a
Table 1 | Recent adoptive cell therapy trials using CAR engineeredT cells.
Target antigen Disease CAR signaling domain ClinicalTrial.gov identifier Clinical center
CD19 B-CLL CD28-CD3ζ NCT00466531 MSKCC
CD19 B-ALL CD28-CD3ζ NCT01044069 MSKCC
CD19 Leukemia CD28-CD3ζ NCT01416974 MSKCC
CD19 Leukemia/lymphoma CD28-CD3ζ NCT00924326 NCI
CD19 Leukemia/lymphoma CD28-CD3ζ NCT01087294 NCI
CD19 Leukemia/lymphoma CD28-CD3ζ vs. CD3ζ NCT00586391 BCM
CD19 B-NHL/CLL CD28-CD3ζ vs. CD3ζ NCT00608270 BCM
CD19 Advanced B-NHL/CLL CD28-CD3ζ vs. CD3ζ NCT00709033 BCM
CD19 ALL post-HSCT CD28-CD3ζ NCT00840853 BCM
CD19 Leukemia/lymphoma CD137-CD3ζ NCT01029366 UP
CD19 B-lymphoid malignancies CD28-CD3ζ NCT00968760 MDACC
CD19 B-lineage malignancies CD28-CD3ζ NCT01362452 MDACC
CD20 Mantle cell lymphoma/indolent B-NHL CD28-CD137-CD3ζ NCT00621452 FHCRC
PMSA Prostate cancer CD28-CD3ζ NCT01140373 MSKCC
CEA Breast cancer CD28-CD3ζ NCT00673829 RWMC
CEA Colorectal cancer CD28-CD3ζ NCT00673322 RWMC
Her2/neu Lung cancer CD28-CD3ζ NCT00889954 BCM
Her2/neu Osteosarcoma CD28-CD3ζ NCT00902044 BCM
Her2/neu Glioblastoma CD28-CD3ζ NCT01109095 BCM
Kappa light chain B-NHL and B-CLL CD28-CD3ζ vs. CD3ζ NCT00881920 BCM
MSKCC, Memorial Sloan-Kettering Cancer Center; NCI, National Cancer Institute; BCM, Baylor College of Medicine; RWMC, Roger Williams Medical Center; UP,
University of Pennsylvania; MDACC, M.D. Anderson Cancer Center; FHCRC, Fred Hutchinson Cancer Research Center.
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CD19+ CLL patient with CD28-CD3ζ CAR T cells was attributed
to an extravasation of a latent bacterial infection subsequent to
lymphodepletion (51). Despite the observed severe adverse events,
MHC-independent targeting of cancer cells by CAR modified T
cells showed promise in controlling CD19+ leukemia in the long-
term; currently initiated and future trials will address whether solid
cancer lesions will also successfully be targeted and controlled by
CAR T cells.
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